Evaluation of the Clinical Effectiveness of the Salmeterol/Fluticasone Fixed-Dose Combination Delivered via the Elpenhaler^® Device in Greek Patients with Chronic Obstructive Pulmonary Disease and Comorbidities: The AEOLOS Study.

ABSTRACT:

Background

Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory lung disease characterized by airflow limitation that is not completely reversible. The fixed-dose combination of salmeterol and fluticasone propionate (SFC) has been approved as a treatment for COPD patients with a history of recurrent exacerbations and significant symptoms despite regular bronchodilator therapy. In the present study, we evaluated the change in FEV₁, mMRC dyspnea score and satisfaction in COPD patients with at least one comorbidity versus those without comorbidities treated with a fixed-dose SFC via the Elpenhaler^® device for 12 months.

Methods

A 12-month multicenter prospective, observational study (NCT02978703) was designed. Data were collected during the enro

SUBMITTER: Steiropoulos P 

PROVIDER: S-EPMC8621702 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature